Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening in 1077 Women After BRCA Testing

被引:25
|
作者
Mannis, Gabriel N. [1 ]
Fehniger, Julia E. [2 ]
Creasman, Jennifer S. [3 ,4 ]
Jacoby, Vanessa L. [3 ]
Beattie, Mary S. [2 ,4 ]
机构
[1] Univ Calif San Francisco, Div Hematol Oncol, Dept Internal Med, San Francisco, CA 94117 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Canc Risk Program, San Francisco, CA 94117 USA
[3] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94117 USA
[4] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94117 USA
关键词
BREAST-CANCER; CLINICAL CHARACTERISTICS; MUTATION CARRIERS; REDUCTION; TIME; METAANALYSIS; ASSOCIATION; PREDICTORS; ULTRASOUND; EFFICACY;
D O I
10.1001/2013.jamainternmed.962
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: For women at potentially increased risk for ovarian cancer, data regarding screening and risk reduction are limited. Previous studies have reported on the behaviors of BRCA mutation carriers, but less is known about the behaviors of non-BRCA carriers. We surveyed a large cohort of women after BRCA testing to identify the prevalence and posttest predictors of risk-reducing and screening interventions. Methods: A median of 3.7 years after BRCA testing, 1447 women who received genetic counseling and BRCA testing at 2 hospital sites were surveyed, with a 77.6% response rate. We analyzed data from 1077 survey respondents. We performed univariate and multivariate logistic regression analyses to identify predictors of risk-reducing salpingo-oophorectomy (RRSO), screening transvaginal ultrasonography (TVUS), and screening serum cancer antigen 125 (CA-125). Results: Among the respondents, 201 women (18.7%) received positive test results for a deleterious mutation, 103 women (9.6%) received true-negative results, and 773 women (71.8%) received uninformative results. Over-all, 19.1% of eligible women underwent RRSO and 39.6% used screening procedures. A positive BRCA result predicted RRSO (odds ratio [OR], 28.1; 95% CI, 16.2-48.6), TVUS (9.5 [4.3-21.0]), and serum CA-125 (13.0 [5.5-29.0]). Similarly, a true-negative BRCA result reduced the OR for RRSO (0.1 [0.0-0.6]), TVUS (0.2 [0.1-0.5]), and serum CA-125 (0.3 [0.1-0.7]). Of the 71.8% of women who received uninformative results after BRCA testing, 12.3% subsequently underwent RRSO, 33.8% reported ever having undergone screening serum CA-125 since BRCA testing, and 37.3% reported ever having undergone screening TVUS since BRCA testing. Conclusions: Results of BRCA testing strongly predict RRSO and ovarian cancer screening. Use of RRSO and ovarian screening was reported in a sizable percentage of non-BRCA carriers despite insufficient data to determine the effectiveness of these interventions. JAMA Intern Med. 2013; 173(2):96-103. Published online December 17, 2012. doi:10.1001/2013.jamainternmed.962
引用
收藏
页码:96 / 103
页数:8
相关论文
共 50 条
  • [1] Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations
    Shu, Catherine A.
    Pike, Malcolm C.
    Jotwani, Anjali R.
    Friebel, Tara M.
    Soslow, Robert A.
    Levine, Douglas A.
    Nathanson, Katherine L.
    Konner, Jason A.
    Arnold, Angela G.
    Bogomolniy, Faina
    Dao, Fanny
    Olvera, Narciso
    Bancroft, Elizabeth K.
    Goldfrank, Deborah J.
    Stadler, Zsofia K.
    Robson, Mark E.
    Brown, Carol L.
    Leitao, Mario M., Jr.
    Abu-Rustum, Nadeem R.
    Aghajanian, Carol A.
    Blum, Joanne L.
    Neuhausen, Susan L.
    Garber, Judy E.
    Daly, Mary B.
    Isaacs, Claudine
    Eeles, Rosalind A.
    Ganz, Patricia A.
    Barakat, Richard R.
    Offit, Kenneth
    Domchek, Susan M.
    Rebbeck, Timothy R.
    Kauff, Noah D.
    JAMA ONCOLOGY, 2016, 2 (11) : 1434 - 1440
  • [2] Risk-reducing salpingo-oophorectomy for BRCA mutation carriers
    Haldar, Krishnayan
    Crawford, Robin
    MATURITAS, 2010, 67 (03) : 290 - 290
  • [3] RISK-REDUCING SALPINGO-OOPHORECTOMY IN BRCA MUTATION PATIENTS
    Loizzi, Vera
    Arezzo, Francesca
    Mongelli, Michele
    Kardhashi, Anila
    Silvestris, Erica
    Cazzolla, Ambrogio
    Difonzo, Tommaso
    Cerbone, Marco
    Battista, Gaia
    Quarto, Pietro
    Memmola, Massimiliano
    Cormio, Gennaro
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A342 - A342
  • [4] Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy
    Powell, CB
    GYNECOLOGIC ONCOLOGY, 2006, 100 (01) : 1 - 2
  • [5] Quality of life after risk-reducing salpingo-oophorectomy in women with a pathogenic BRCA variant
    Zilski, Nicole
    Speiser, Dorothee
    Bartley, Julia
    Roehle, Robert
    Blohmer, Jens-Uwe
    Keilholz, Ulrich
    Goerling, Ute
    JOURNAL OF SEXUAL MEDICINE, 2023, 21 (01): : 33 - 39
  • [6] Quality of life after risk-reducing salpingo-oophorectomy in BRCA carrier
    Jang, Y.
    Kang, E.
    Kim, E.
    Chae, S.
    Kim, H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Risk-reducing salpingo-oophorectomy among Chinese women at increased risk of breast and ovarian cancer
    Feng, Zheng
    Zuo, Ke
    Ju, Xingzhu
    Chen, Xiaojun
    Yang, Wentao
    Wen, Hao
    Yu, Lin
    Wu, Xiaohua
    JOURNAL OF OVARIAN RESEARCH, 2023, 16 (01)
  • [8] Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer
    Bettina Meiser
    Melanie A. Price
    Phyllis N. Butow
    Janan Karatas
    Judy Wilson
    Louise Heiniger
    Brandi Baylock
    Margaret Charles
    Sue-Anne McLachlan
    Kelly-Anne Phillips
    Familial Cancer, 2013, 12 : 101 - 109
  • [9] Risk-reducing salpingo-oophorectomy among Chinese women at increased risk of breast and ovarian cancer
    Zheng Feng
    Ke Zuo
    Xingzhu Ju
    Xiaojun Chen
    Wentao Yang
    Hao Wen
    Lin Yu
    Xiaohua Wu
    Journal of Ovarian Research, 16
  • [10] Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer
    Meiser, Bettina
    Price, Melanie A.
    Butow, Phyllis N.
    Karatas, Janan
    Wilson, Judy
    Heiniger, Louise
    Baylock, Brandi
    Charles, Margaret
    McLachlan, Sue-Anne
    Phillips, Kelly-Anne
    FAMILIAL CANCER, 2013, 12 (01) : 101 - 109